Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

2.

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B; Management of Arterial Hypertension of the European Society of Hypertension.; European Society of Cardiology..

J Hypertens. 2007 Jun;25(6):1105-87. No abstract available. Erratum in: J Hypertens. 2007 Aug;25(8):1749.

PMID:
17563527
3.

Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis.

Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, Hennig M, Zanchetti A.

J Hypertens. 2007 May;25(5):1087-94.

PMID:
17414674
4.

Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes.

Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S; INNOVATION Study Group..

Diabetes Care. 2007 Jun;30(6):1577-8. Epub 2007 Mar 26. No abstract available.

PMID:
17389334
5.

Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.

Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.

Diabet Med. 2007 May;24(5):486-93. Epub 2007 Mar 15.

PMID:
17367311
6.

Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.

Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM.

Diabetes Care. 2007 Jun;30(6):1351-6. Epub 2007 Mar 2. Erratum in: Diabetes Care. 2007 Sep;30(9):2421.

PMID:
17337492
7.

Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.

Symeonides P, Koulouris S, Vratsista E, Triantafyllou K, Ioannidis G, Thalassinos N, Katritsis D.

Eur J Echocardiogr. 2007 Dec;8(6):480-6. Epub 2006 Nov 17.

PMID:
17113349
8.

Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.

Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E, Böger RH.

Metabolism. 2006 Sep;55(9):1159-64.

PMID:
16919533
9.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.

Am J Kidney Dis. 2006 Jul;48(1):8-20. Review.

PMID:
16797382
10.

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.

Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM; LIFE Study Investigators..

J Hypertens. 2006 Apr;24(4):775-81.

PMID:
16531808
11.

Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.

Galzerano D, Tammaro P, del Viscovo L, Lama D, Galzerano A, Breglio R, Tuccillo B, Paolisso G, Capogrosso P.

Am J Hypertens. 2005 Dec;18(12 Pt 1):1563-9.

PMID:
16364826
12.

Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.

Petrovic I, Petrovic D, Vukovic N, Zivanovic B, Dragicevic J, Vasiljevic Z, Babic R.

J Int Med Res. 2005;33 Suppl 1:39A-49A.

PMID:
16222899
13.

Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.

Sengul AM, Altuntas Y, Kürklü A, Aydin L.

Diabetes Res Clin Pract. 2006 Feb;71(2):210-9. Epub 2005 Aug 19.

PMID:
16112244
14.

The ONTARGET/TRANSCEND Trial Programme: baseline data.

Sleight P.

Acta Diabetol. 2005 Apr;42 Suppl 1:S50-6.

PMID:
15868120
15.

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y.

Hypertension. 2005 Feb;45(2):198-202. Epub 2005 Jan 17.

16.

Prognostic significance of left ventricular mass change during treatment of hypertension.

Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B.

JAMA. 2004 Nov 17;292(19):2350-6.

PMID:
15547162
17.

Preventing microalbuminuria in type 2 diabetes.

Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators..

N Engl J Med. 2004 Nov 4;351(19):1941-51. Epub 2004 Oct 31.

18.

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.

Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group..

N Engl J Med. 2004 Nov 4;351(19):1952-61. Epub 2004 Oct 31. Erratum in: N Engl J Med. 2005 Apr 21;352(16)1731.

19.

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Circulation. 2004 Aug 24;110(8):921-7. Epub 2004 Aug 9.

Supplemental Content

Support Center